";s:4:"text";s:3186:" The potential for this pathogen to infect non-cystic fibrosis patients is limited and its epidemiology is poorly understood.
Jane L Burns.
George Zahariadis. We were interested to read recently in the Journal of ‘cepacia syndrome’ being successfully treated by combined nebulised and intravenous (IV) therapy with both meropenem and tobramycin in a 31 year old woman with cystic fibrosis (CF) and an en-bloc liver–pancreas transplant . Burkholderia cepacia is a gram-negative bacilli leading to pneumonia with poor prognosis and usually seen in patients with immunosuppression or with structural lung diseases. 1993 Type species ATCC 25416 CCUG 12691 and 13226 CFBP 2227 CIP 80.24 DSM 7288 HAMBI …
Michelle H Levy. The clinical manifestations of BCC infection are varied but can include cepacia syndrome, which is a rapidly progressing necrotising pneumonia with an almost universally fatal outcome.
Cepacia-Like Syndrome Caused by Burkholderia mutivorans.
Decisions on the treatment of infections with B. cepacia should be made on a case-by-case basis. Pulmonary colonisation can lead to an accelerated decline in lung function. Treatment of B. cepacia infection. Case Presentation: A 52-year-old diabetic male came with chief complains of fever since last 15 days and swelling of left knee joint since last 3 days. Burkholderia cepacia complex (BCC) is a group of 17 closely related bacterial species that can cause pulmonary infection in patients with cystic fibrosis (CF). Burkholderia (formerly Pseudomonas ) cepacia complex is a known serious threat to patients with cystic fibrosis, in whom it has the potential to cause the fatal combination of necrotizing pneumonia, worsening respiratory failure, and bacteremia, known as Cepacia syndrome. Burkholderia cepacia is a plant phytogen and is known as a hardy and versatile organism. In the only previously published report of successful treatment of cepacia syndrome, Kazachkov et al. Successful treatment of cepacia syndrome K. Grimwood a,⁎, T.J. Kidd b, M. Tweed c a Departments of Paediatrics and Child Health, University of Otago, Wellington, Wellington Hospital, Capital and Coast Health, PO Box 7343, Wellington 6015, New Zealand b Queensland Paediatric Infectious Diseases Laboratory, Queensland Children's Medical Research Institute, Royal Children's Hospital, The potential for this pathogen to infect non-cystic fibrosis patients is limited and its epidemiology is poorly understood. This case highlights the possible role of cyclosporin in the treatment of cepacia syndrome. Patient 1 was admitted with ‘cepacia syndrome’ with extensive pulmonary consolidations and positive blood cultures for Burkholderia cenocepacia IIIA. Over the past two decades it has emerged as a pathogen in the cystic fibrosis (CF) community, with devastating effects.